Pr MD - Erytech Pharma Consultant Board

Insider

Pr MD is Consultant Board of Erytech Pharma SA
Phone33 4 78 74 44 38
Webhttps://www.erytech.com

Erytech Pharma Management Efficiency

The company has return on total asset (ROA) of (0.3014) % which means that it has lost $0.3014 on every $100 spent on assets. This is way below average. Erytech Pharma's management efficiency ratios could be used to measure how well Erytech Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Erytech Pharma SA currently holds 13.57 M in liabilities with Debt to Equity (D/E) ratio of 1.0, which is about average as compared to similar companies. Erytech Pharma SA has a current ratio of 2.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Erytech Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Clark ChengAptorum Group Ltd
44
Roeland NusseSurrozen
75
CGMA CPASoligenix
53
Jeffrey PharmDNutriband
55
Bart AndersonExicure
N/A
David JinAvenue Therapeutics
34
Nick RigopoulosXORTX Therapeutics
N/A
Pascal CaiseyGenfit
56
Pr StaelsGenfit
62
, MBAMolecular Partners AG
51
Chung HuenAptorum Group Ltd
45
Erin ButlerArmata Pharmaceuticals
N/A
MBA MDIkena Oncology
59
Christopher GarciaSurrozen
N/A
MPA MDUnicycive Therapeutics
52
Timothy DyerAddex Therapeutics
57
Wenyuan ShiArmata Pharmaceuticals
N/A
JeanPhilippe RocherAddex Therapeutics
65
David MacDonaldXORTX Therapeutics
61
Thomas BaetzGenfit
51
Peter RhodeHCW Biologics
66
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. The company was incorporated in 2004 and is headquartered in Lyon, France. Erytech Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people. Erytech Pharma SA (ERYP) is traded on NASDAQ Exchange in USA and employs 49 people.

Management Performance

Erytech Pharma SA Leadership Team

Elected by the shareholders, the Erytech Pharma's board of directors comprises two types of representatives: Erytech Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Erytech. The board's role is to monitor Erytech Pharma's management team and ensure that shareholders' interests are well served. Erytech Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Erytech Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Gil BVBA, CEO Director
Iman MD, Chief Officer
Philip Lorenzi, Consultant Board
AnneCcile Fumey, HR Director
Brian Schwab, Chief Counsel
Naomi Eichenbaum, Director Relations
Eric Soyer, CFO, COO
Bridget Bax, Consultant Board
Jrme PharmD, Chief Operations
Pr MD, Consultant Board

Erytech Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Erytech Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Erytech Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Erytech Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Erytech Pharma will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Molson Coors could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molson Coors when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molson Coors - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molson Coors Brewing to buy it.
The correlation of Molson Coors is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molson Coors moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molson Coors Brewing moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molson Coors can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Erytech Stock

If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Money Managers
Screen money managers from public funds and ETFs managed around the world
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins